What Segal’s 2027 healthcare cost forecast means for employers, payers and PBMs
Segal projects a 9.9% medical plan cost trend for 2027 as GLP-1 drugs, AI coding and arbitration intensify employer cost pressure.
Segal projects a 9.9% medical plan cost trend for 2027 as GLP-1 drugs, AI coding and arbitration intensify employer cost pressure.
Medicare coverage gives ColoSense a bigger test: can stool RNA screening move from FDA approval to real colorectal cancer adoption?
Imbed Biosciences secured CMS HCPCS code A2040 for Microlyte PainGuard. Read what it changes for wound care adoption, billing, and reimbursement.